» Articles » PMID: 11484689

Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2001 Aug 4
PMID 11484689
Citations 195
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Most patients with familial primary pulmonary hypertension have defects in the gene for bone morphogenetic protein receptor II (BMPR2), a member of the transforming growth factor beta (TGF-beta) superfamily of receptors. Because patients with hereditary hemorrhagic telangiectasia may have lung disease that is indistinguishable from primary pulmonary hypertension, we investigated the genetic basis of lung disease in these patients.

Methods: We evaluated members of five kindreds plus one individual patient with hereditary hemorrhagic telangiectasia and identified 10 cases of pulmonary hypertension. In the two largest families, we used microsatellite markers to test for linkage to genes encoding TGF-beta-receptor proteins, including endoglin and activin-receptor-like kinase 1 (ALK1), and BMPR2. In subjects with hereditary hemorrhagic telangiectasia and pulmonary hypertension, we also scanned ALK1 and BMPR2 for mutations.

Results: We identified suggestive linkage of pulmonary hypertension with hereditary hemorrhagic telangiectasia on chromosome 12q13, a region that includes ALK1. We identified amino acid changes in activin-receptor-like kinase 1 that were inherited in subjects who had a disorder with clinical and histologic features indistinguishable from those of primary pulmonary hypertension. Immunohistochemical analysis in four subjects and one control showed pulmonary vascular endothelial expression of activin-receptor-like kinase 1 in normal and diseased pulmonary arteries.

Conclusions: Pulmonary hypertension in association with hereditary hemorrhagic telangiectasia can involve mutations in ALK1. These mutations are associated with diverse effects, including the vascular dilatation characteristic of hereditary hemorrhagic telangiectasia and the occlusion of small pulmonary arteries that is typical of primary pulmonary hypertension.

Citing Articles

Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).

Forbes L, Bauer N, Bhadra A, Bogaard H, Choudhary G, Goss K Pulm Circ. 2025; 15(1):e70027.

PMID: 39749110 PMC: 11693987. DOI: 10.1002/pul2.70027.


Pulmonary vascular manifestations of hereditary haemorrhagic telangiectasia.

Cullivan S, Kevane B, McCullagh B, OConnor T, Condliffe R, Gaine S Pulm Circ. 2024; 14(4):e70007.

PMID: 39588537 PMC: 11586239. DOI: 10.1002/pul2.70007.


Human umbilical cord mesenchymal stem cell-derived treatment of severe pulmonary arterial hypertension.

Hansmann G, Chouvarine P, Diekmann F, Giera M, Ralser M, Mulleder M Nat Cardiovasc Res. 2024; 1(6):568-576.

PMID: 39195868 PMC: 11358026. DOI: 10.1038/s44161-022-00083-z.


Mechanisms and treatment of pulmonary arterial hypertension.

Ghofrani H, Gomberg-Maitland M, Zhao L, Grimminger F Nat Rev Cardiol. 2024; 22(2):105-120.

PMID: 39112561 DOI: 10.1038/s41569-024-01064-4.


Pulmonary Hypertension in Sickle Cell Disease: Novel Findings of Gene Polymorphisms Related to Pathophysiology.

Chatzidavid S, Flevari P, Tombrou I, Anastasiadis G, Dimopoulou M Int J Mol Sci. 2024; 25(9).

PMID: 38732015 PMC: 11084253. DOI: 10.3390/ijms25094792.